Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer.

MLA

Burcher, Kimberly M., et al. “Study Protocol: Phase II Study to Evaluate the Effect of Cetuximab Monotherapy after Immunotherapy with PD-1 Inhibitors in Patients with Head and Neck Squamous Cell Cancer.” Therapeutic Advances in Medical Oncology, vol. 16, Jan. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1177/17588359231217959.

APA

Burcher, K. M., Bloomer, C. H., Gavrila, E., Kalada, J. M., Chang, M. J., Gebeyehu, R. R., Song, A. H., Khoury, L. M., Lycan, T. W., Kinney, R., D’Agostino Jr., R., Bunch, P. M., Shukla, K., Triozzi, P., Furdui, C. M., Zhang, W., & Porosnicu, M. (2024). Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer. Therapeutic Advances in Medical Oncology, 16, 1–12. https://doi.org/10.1177/17588359231217959

Chicago

Burcher, Kimberly M., Chance H. Bloomer, Elena Gavrila, John M. Kalada, Mark J. Chang, Rediet R. Gebeyehu, Alexander H. Song, et al. 2024. “Study Protocol: Phase II Study to Evaluate the Effect of Cetuximab Monotherapy after Immunotherapy with PD-1 Inhibitors in Patients with Head and Neck Squamous Cell Cancer.” Therapeutic Advances in Medical Oncology 16 (January): 1–12. doi:10.1177/17588359231217959.